aibio
Debt Financing ·
BCAL Diagnostics details convertible note draws under its $10 million facility
After raising $3.1 million by February, BCAL drew further notes and plans more, which use up its Listing Rule 7.1 capacity.
BDX BECTON DICKINSON & CO
BECTON DICKINSON & CO (BDX) news BDX convertible notes news
Latest BECTON DICKINSON & CO news
We have not published a story on BECTON DICKINSON & CO yet. When there is news, it will appear here.
BECTON DICKINSON & CO annual financials
| Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 |
|---|---|---|
| Revenue | $21.84 billion | $20.18 billion |
| Research and development | $1.26 billion | $1.19 billion |
| Net income (loss) | $1.68 billion | $1.71 billion |
| Cash and equivalents | $567.0 million | $1.72 billion |
Questions about BECTON DICKINSON & CO
Has BECTON DICKINSON & CO sold convertible notes?
Our latest story on this, dated Aug 21, 2026: "BCAL Diagnostics details convertible note draws under its $10 million facility". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of BECTON DICKINSON & CO?
BECTON DICKINSON & CO trades under the ticker BDX on NYSE.
Where is BECTON DICKINSON & CO listed?
BECTON DICKINSON & CO is listed on NYSE.
Which country or territory is BECTON DICKINSON & CO listed under?
Our directory records BECTON DICKINSON & CO under United States.
Does aibio.space cover BECTON DICKINSON & CO?
aibio.space lists BECTON DICKINSON & CO among 2,820 public biotech companies and publishes its news here as stories appear.
What was BECTON DICKINSON & CO's revenue last year?
$21.84 billion for the fiscal year ended Sep 30, 2025, as reported to the SEC.
Is BECTON DICKINSON & CO profitable?
BECTON DICKINSON & CO reported net income of $1.68 billion for the fiscal year ended Sep 30, 2025, per its annual report to the SEC.
How much does BECTON DICKINSON & CO spend on research and development?
$1.26 billion in the fiscal year ended Sep 30, 2025, per its annual report.
How much cash does BECTON DICKINSON & CO have?
$708.0 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest BECTON DICKINSON & CO (BDX) stock news?
Our latest story on BECTON DICKINSON & CO, dated Aug 21, 2026: "BCAL Diagnostics details convertible note draws under its $10 million facility". After raising $3.1 million by February, BCAL drew further notes and plans more, which use up its Listing Rule 7.1 capacity. Source.
How can I follow BECTON DICKINSON & CO (BDX) news?
Press Follow on this page to add BECTON DICKINSON & CO to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming BECTON DICKINSON & CO so far, in Debt Financing.
Investor discussion: BECTON DICKINSON & CO
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Stock chart
Listing details
- Company
- BECTON DICKINSON & CO
- Ticker
- BDX
- Listing
- NYSE
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction